Clinical differences between acute and chronic asthenic disorders: A case report
TL;DR
A diagnostic framework for identifying coexisting conditions in patients with ARs is presented to enhance early disease detection and facilitate optimal pharmacological management.
Abstract
Asthenic disorders (ARs) present a significant and frequently addressed medical concern. Currently, there is no standardized classification of ARs based on severity and duration of symptoms. Acute ARs are typically linked to sudden events, infections, injuries, or vascular incidents. Symptoms manifest rapidly and typically persist for 1 to 3 months. Initial neurological symptoms may include general weakness, apathy, reduced appetite, episodic memory disturbances, challenges in information retention, reduced concentration, irritability, aggressiveness, and, less frequently, symptoms of depression or low mood. Autonomic symptoms are prominent, manifesting as fluctuations in blood pressure, tachycardia, pulse variability, various types of pain or discomfort, skin pallor or redness, sensations of heat with a normal body temperature, increased chilliness, and hyperhidrosis. Chronic ARs are associated with longstanding somatic conditions, including post-viral syndromes following SARS-CoV-2 (COVID-19) infections. A salient characteristic of chronic asthenia is its progressive nature, with symptoms persisting for more than three months. This report outlines a case involving a patient who experienced prolonged symptoms of weakness, fatigue, diminished attention span, emotional instability, various physical discomforts, gastrointestinal disturbances (such as abdominal pain, diarrhea, and dyspepsia), and severe headaches following COVID-19. These symptoms developed gradually, worsening and complicating the diagnostic process. Two years after the disease onset, the patient presented with excessive sweating, worsening weakness, persistent pain localized in the head, back, and joints, a sensation of breathlessness – particularly during exertion – and a dry cough. Following a comprehensive evaluation, the diagnosis of chronic obstructive pulmonary disease was established. During the diagnostic phase, a neuromodulatory agent (fonturacetam) was introduced to the therapeutic regimen, selected for its compatibility with the existing treatment protocol for chronic obstructive pulmonary disease. This article presents a diagnostic framework for identifying coexisting conditions in patients with ARs to enhance early disease detection and facilitate optimal pharmacological management.